Purpura, Thrombocytopenic, Idiopathic: all 521 studies

Page 2 of 6. Open to participants first (158), then studies with results posted, then the rest; newest registration first within each.

• IASO-782 in Autoimmune Hematological DiseasesRecruitingNCT06534021Phase 1
• Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.RecruitingNCT06531018Phase 1/2
• Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)RecruitingNCT06519565Early Phase 1
• The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITPRecruitingNCT06479317Not applicable
• The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITPRecruitingNCT06479304Not applicable
• The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITPRecruitingNCT06479291Not applicable
• TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment TerminationRecruitingNCT06478537Phase 2
• Observational Study on the Outcome of Patients With ITP Who Underwent Splenectomy After 2010Not yet recruitingNCT06466824
• Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune DiseasesNot yet recruitingNCT06417398Early Phase 1
• Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)RecruitingNCT06371417Phase 1
• Efficacy and Safety of CAR-T Cells Therapy for Chronic or Refractory Primary Immune Thrombocytopenia (ITP)RecruitingNCT06352281Phase 1/2
• An Clinical Study of CD19 CAR NK Cells for the Treatment of Refractory Primary Immune ThrombocytopeniaRecruitingNCT06337474Early Phase 1
• Avatrombopag in the Treatment of Pediatric Immune ThrombocytopeniaRecruitingNCT06281327Phase 2
• Explore the Relationship Between Platelet Count and Bleeding Score in ITPRecruitingNCT06273956
• Teriflunomide for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingNCT06190145Phase 2
• The Combination of Teriflunomide and Danazol for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingNCT06176911Phase 2
• Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06168851Phase 2
• Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic PurpuraNot yet recruitingNCT06137105
• Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06107582
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT06094881Phase 2
• Immune Markers in Pediatric ITP on Second Line TherapyNot yet recruitingNCT06093529
• Use of Vitamin D as An Adjuvant Treatment in Children With Chronic Idiopathic Thrombocytopenic PurpuraNot yet recruitingNCT06073925Early Phase 1
• Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune ThrombocytopeniaRecruitingNCT06004856Phase 3
• A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune ThrombocytopeniaRecruitingNCT05995054Phase 2
• High-dose Dexamethasone Plus Hetrombopag vs High-dose Dexamethasone Alone as Frontline Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Prospective, Multicenter, Randomized TrialRecruitingNCT05943691Phase 2
• OBS'CEREVANCE: French Cohort of Pediatric Autoimmune CytopeniaRecruitingNCT05937828
• Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune ThrombocytopeniaRecruitingNCT05932524Phase 2
• Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune NeutropeniaRecruitingNCT05931718
• CNCT19 Cell Injection for Refractory Systemic Lupus ErythematosusEnrolling by invitationNCT05930314Early Phase 1
• Immune Thrombocytopenia Management in AdultsRecruitingNCT05861297Phase 4
• Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune ThrombocytopeniaRecruitingNCT05852847Phase 2
• TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)RecruitingNCT05718856Phase 4
• Biologic Characterization of Patients With ITPRecruitingNCT05694325Not applicable
• The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune ThrombocytopeniaRecruitingNCT05599880Phase 2
• Short-course High-dose Prednisone and Dexamethasone in Children With ITPRecruitingNCT05522465Phase 4
• Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in ChildrenRecruitingNCT05520892Phase 4
• Optimization of Glucocorticoid Taper Strategies for SLE-ITPEnrolling by invitationNCT05506033Not applicable
• Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune ThrombocytopeniaNot yet recruitingNCT05459649Phase 2
• Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaNot yet recruitingNCT05369377Phase 2
• The Combination of Zanubrutinib and High-dose Dexamethasone as First-line Treatment in Adult Immune ThrombocytopeniaNot yet recruitingNCT05369364Phase 2
• Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaRecruitingNCT05338190Phase 3
• An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AANot yet recruitingNCT05333861
• A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune ThrombocytopeniaRecruitingNCT05214391Phase 2
• ITP Registry and Accompanying Biospecimen CollectionRecruitingNCT05152238
• Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04993885Phase 2
• IgIV Plus Prednisone vs High-dose Dexamethasone for ITPRecruitingNCT04968899Phase 3
• TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With AutoantibodiesRecruitingNCT04915482Phase 2/3
• TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 YearsRecruitingNCT04890041Not applicable
• Managed Access Programs for ETB115, EltrombopagAvailableNCT04837703
• Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at DiagnosisRecruitingNCT04800458Not applicable
• Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in AdultsRecruitingNCT04518475Phase 4
• Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic PurpuraRecruitingNCT04323748Phase 1
• Safety and Efficacy of Fecal Microbiota TransplantationRecruitingNCT04014413Not applicable
• Biological Bank for the Patients Followed in a Constitutive Reference Center for Autoimmune CytopeniaRecruitingNCT04005638
• Evaluation of Immune Status Before and After Splenectomy in Immune Thrombocytopenia PatientsRecruitingNCT03998059
• French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic AnemiaRecruitingNCT02877706
• Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)RecruitingNCT02821572
• Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875
• Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated CytopeniasTerminatedNCT05502783Phase 2Results posted
• Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in AdultsCompletedNCT05422365Phase 3Results posted
• Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITPCompletedNCT05369208Phase 3Results posted
• Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological DisordersTerminatedNCT05086744Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune ThrombocytopeniaCompletedNCT04687072Phase 3Results posted
• A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)CompletedNCT04669600Phase 2Results posted
• Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or RomiplostimCompletedNCT04638829Phase 4Results posted
• A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedNCT04596995Phase 3Results posted
• Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)CompletedNCT04562766Phase 3Results posted
• Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 MonthsCompletedNCT04516967Phase 3Results posted
• A Study to Assess Efficacy and Safety of Eltrombopag in Combination With a Short Course of Dexamethasone in Patients With Newly Diagnosed ITPCompletedNCT04346654Phase 2Results posted
• A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune ThrombocytopeniaCompletedNCT04278924Phase 2Results posted
• A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedNCT04224688Phase 3Results posted
• A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune ThrombocytopeniaStatus unknownNCT04214951Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)TerminatedNCT04200456Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).CompletedNCT04188379Phase 3Results posted
• A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788CompletedNCT04132050Phase 3Results posted
• Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)CompletedNCT04056195Phase 2Results posted
• Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in ChildrenCompletedNCT03939637Phase 3Results posted
• Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) PatientsTerminatedNCT03866577Phase 1/2Results posted
• A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITPCompletedNCT03524612Phase 2Results posted
• A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)CompletedNCT03395210Phase 2Results posted
• A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347TerminatedNCT03275740Phase 1Results posted
• Drug Use Surveillance of Takecab for "Supplement to Helicobacter Pylori Eradication"CompletedNCT03219723Results posted
• Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune ThrombocytopeniaCompletedNCT02718716Phase 2Results posted
• Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune ThrombocytopeniaCompletedNCT02334813Phase 3Results posted
• Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)CompletedNCT02279173Phase 3Results posted
• Study to Evaluate Safety and Efficacy in Adult Subjects With ITPCompletedNCT02273960Phase 1/2Results posted
• A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)CompletedNCT02201290Phase 3Results posted
• Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02077192Phase 3Results posted
• A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076412Phase 3Results posted
• A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT02076399Phase 3Results posted
• Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).TerminatedNCT02009761Phase 1Results posted
• Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)CompletedNCT01963260Phase 1Results posted
• Safety and Efficacy of Eltrombopag at Escalated DosesCompletedNCT01880047Phase 2Results posted
• Eltrombopag Phase III Study In Chinese Chronic ITP PatientsCompletedNCT01762761Phase 3Results posted
• Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.CompletedNCT01520909Phase 3Results posted
• Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsCompletedNCT01444417Phase 3Results posted
• Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)CompletedNCT01438840Phase 3Results posted
• A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)TerminatedNCT01433978Phase 3Results posted
• A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)CompletedNCT01390649Phase 4Results posted
• Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune ThrombocytopeniaCompletedNCT01349790Phase 3Results posted

← Purpura, Thrombocytopenic, Idiopathic overview